| Size | Price | Stock | Qty |
|---|---|---|---|
| 50mg |
|
||
| 100mg |
|
||
| Other Sizes |
| Targets |
2'-Deoxy-2'-fluoro-5-iodouridine targets RNA polymerase, which is essential for the transcription of RNA. As a purine nucleoside analog, it interferes with nucleic acid synthesis, leading to inhibition of cell proliferation. The compound is also a substrate for HSV1-thymidine kinase (HSV1-tk), allowing for selective accumulation in HSV1-tk-expressing tumors when labeled with 123I.
|
|---|---|
| ln Vitro |
2'-Deoxy-2'-fluoro-5-iodouridine demonstrates in vitro anticancer activity against various cancer types, including breast, lung, and pancreatic cancer. As a purine nucleoside analog, it has broad-spectrum antitumor activity targeting indolent lymphoid malignancies. The compound's activity is typically assessed in cell viability assays using cancer cell lines, where it exhibits concentration-dependent inhibition of proliferation.
|
| ln Vivo |
In vivo activity of 2'-deoxy-2'-fluoro-5-iodouridine has been demonstrated through its use as a imaging agent. When labeled with 123I, the compound accumulates selectively in tumors expressing the HSV1-tk gene, enabling non-invasive imaging of gene expression. Its anticancer activity suggests potential for in vivo efficacy in cancer models, but further studies are needed to fully characterize its therapeutic potential.
|
| Enzyme Assay |
In vitro enzyme assays for 2'-deoxy-2'-fluoro-5-iodouridine involve measuring its inhibition of RNA polymerase activity. The compound's ability to serve as a substrate for HSV1-thymidine kinase can be assessed using enzymatic assays measuring the phosphorylation of the nucleoside analog. Incorporation of the compound into nucleic acids can be measured using radiolabeled or fluorescently labeled derivatives.
|
| Cell Assay |
In vitro cellular assays for 2'-deoxy-2'-fluoro-5-iodouridine involve treating cancer cell lines with varying concentrations of the compound and measuring cell viability using MTT or other assays. For imaging applications, cells expressing HSV1-tk are treated with 123I-labeled FIRU, and uptake is measured using gamma counting or autoradiography.
|
| Animal Protocol |
In vivo animal experiments for 2'-deoxy-2'-fluoro-5-iodouridine have been conducted for imaging applications. 123I-labeled FIRU is administered to tumor-bearing animals expressing HSV1-tk, and accumulation in tumors is measured using SPECT or PET imaging. The compound's biodistribution and pharmacokinetics can be assessed in these studies.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for 2'-deoxy-2'-fluoro-5-iodouridine are limited. The compound has a molecular weight of 372.09 and a molecular formula of C9H10FIN2O5. It appears as a white to off-white solid. Purity is typically 99.5%. Its absorption, distribution, metabolism, and excretion properties have not been fully characterized.
|
| Toxicity/Toxicokinetics |
Toxicological data for 2'-deoxy-2'-fluoro-5-iodouridine are limited. As a nucleoside analog, it may have potential for toxicity at higher concentrations. The compound is intended for research use only. Standard laboratory safety precautions should be followed when handling this compound.
|
| References | |
| Additional Infomation |
2'-Deoxy-2'-fluoro-5-iodouridine (FIRU) (CAS#: 55612-21-0) has the molecular formula C9H10FIN2O5 and a molecular weight of 372.09. It is a purine nucleoside analog with broad-spectrum anticancer activity. When labeled with 123I, FIRU accumulates selectively in HSV1-tk-expressing tumors for imaging applications. Purity is 99.5%. It is for research use only.
|
| Molecular Formula |
C9H10FIN2O5
|
|---|---|
| Molecular Weight |
372.09
|
| Exact Mass |
371.961
|
| CAS # |
55612-21-0
|
| PubChem CID |
6480472
|
| Appearance |
White to off-white solid powder
|
| Density |
2.2±0.1 g/cm3
|
| Melting Point |
216-218 °C
|
| Index of Refraction |
1.685
|
| LogP |
-0.32
|
| Hydrogen Bond Donor Count |
3
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
2
|
| Heavy Atom Count |
18
|
| Complexity |
418
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C1=C(C(=O)NC(=O)N1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)F)I
|
| InChi Key |
IPVFGAYTKQKGBM-UAKXSSHOSA-N
|
| InChi Code |
InChI=1S/C9H10FIN2O5/c10-5-6(15)4(2-14)18-8(5)13-1-3(11)7(16)12-9(13)17/h1,4-6,8,14-15H,2H2,(H,12,16,17)/t4-,5-,6-,8-/m1/s1
|
| Chemical Name |
1-[(2R,3R,4R,5R)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture and light. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 125 mg/mL (335.94 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (5.59 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.6875 mL | 13.4376 mL | 26.8752 mL | |
| 5 mM | 0.5375 mL | 2.6875 mL | 5.3750 mL | |
| 10 mM | 0.2688 mL | 1.3438 mL | 2.6875 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
